best peptides FAQ

Combination therapy. Adding a peptide like BPC-157 to an existing anti-TNF regimen. Has shown synergistic effects in animal models but lacks controlled human trials. The rationale is mechanistic complementarity: biologics stop the immune attack, while BPC-157 accelerates epithelial repair. If pursuing this approach, coordinate with your gastroenterologist and monitor inflammatory markers (CRP, fecal calprotectin) monthly to detect any loss of biologic efficacy.

No peptide has demonstrated efficacy as monotherapy in moderate-to-severe ulcerative colitis in human trials. The strongest evidence (thymosin alpha-1's Phase II trial) tested it as adjunct therapy alongside mesalamine, not as replacement. Using peptides as sole treatment in active disease risks disease progression, stricture formation, and increased colorectal cancer risk from chronic uncontrolled inflammation.

Take KPV with a small amount of food rather than on an empty stomach—the peptide itself isn't gastric-irritating, but rapid mucosal contact in a fasted state can trigger transient nausea in sensitive individuals. If symptoms persist, switch to enteric-coated capsules that delay release until the small intestine, where KPV's anti-inflammatory action is most needed. Subcutaneous KPV administration bypasses the GI tract entirely but loses the localized mucosal effect that makes oral dosing effective for intestinal inflammation.

Combining oral and topical peptides addresses cellulite through complementary pathways. Oral peptides provide systemic amino acid availability for collagen synthesis throughout dermal tissue, while topical GHK-Cu delivers localised signalling molecules directly to cellulite-affected areas. No published studies have tested this exact combination, but the mechanisms don't interfere with each other. Apply topical peptides after cleansing and before moisturiser to maximise dermal penetration, and take oral collagen on an empty stomach (amino acid absorption competes with dietary protein).

BPC-157 and TB-500 can be used concurrently without known contraindications, though no controlled studies exist confirming additive benefits in humans. A common protocol: BPC-157 daily at 250–500mcg near the injury site, plus TB-500 at 2mg weekly for systemic angiogenesis support. Adding a GH secretagogue like Ipamorelin (200–300mcg nightly) may support broader tissue recovery but won't replace the tendon-specific mechanisms of BPC-157 or TB-500.

Yes, but formulation matters. Hand dermatitis requires occlusive delivery systems that resist washing and friction. Peptide-infused barrier creams with ceramide and cholesterol co-formulation improve penetration and retention. Facial dermatitis, particularly perioral or eyelid involvement, benefits from KPV's non-irritating profile. Corticosteroids near mucosal membranes carry higher systemic absorption risk. TB-4 works well for hand fissures because it accelerates re-epithelialization of disrupted skin, reducing healing time from weeks to days in minor breaks.

You risk conflicting mechanisms. Corticosteroids suppress all collagen synthesis (healthy and pathological), while GHK-Cu promotes organized collagen remodeling. If using both, separate them temporally: corticosteroid injection first to reduce keloid inflammation and volume, then GHK-Cu application 4–6 weeks later during the remodeling phase to guide tissue repair. Simultaneous use may reduce GHK-Cu efficacy because corticosteroids downregulate the growth factor signaling that GHK-Cu depends on.

Switch to TB-500 instead of BPC-157. TB-500's systemic mechanism means injection site proximity to the tendon isn't critical. Subcutaneous abdominal or deltoid injections produce equivalent tissue distribution. Dose at 2–5mg weekly for four weeks, then drop to 2mg biweekly if symptoms improve. The trade-off is that systemic peptides take slightly longer to show localized effects compared to site-specific BPC-157 administration.

Combination protocols are common in research settings but carry compounded risks without proportional evidence of superior outcomes. Both peptides promote angiogenesis and tissue repair through overlapping pathways. Stacking them may increase side effects (localized edema, injection site irritation) without doubling efficacy. If combining, reduce each peptide to the lower end of its dosage range: 250 mcg BPC-157 daily plus 2 mg TB-500 twice weekly. Monitor closely for adverse reactions and discontinue one compound if symptoms worsen.

Avoid products that list 'peptide complex' or 'proprietary blend' without specifying individual compound concentrations. This is a red flag for under-dosed formulations. Clinical efficacy for GHK-Cu requires at least 0.5–1% concentration; palmitoyl peptides need 2–5%; oral collagen peptides require 2.5g minimum per serving. Products that hide concentrations behind marketing language rarely deliver therapeutic doses. Our experience with research-grade compounds shows that purity and dosage matter more than the number of peptides listed on a label.

Cathelicidin upregulation plateaus once serum 25-hydroxyvitamin D reaches 40–50 ng/mL; pushing levels above 60 ng/mL provides no additional antimicrobial peptide benefit and increases hypercalcemia risk. The dose-response relationship is steep between 20–40 ng/mL (each 10 ng/mL increase roughly doubles LL-37 expression) but flattens above that range. If your baseline is already 35 ng/mL, the incremental gain from supplementation is minimal. Focus shifts to SCFA production through fermentable fiber and ensuring adequate dietary zinc (11 mg daily for men, 8 mg for women), which functions as a cofactor in defensin gene transcription.

Pinealon is the compound designed specifically for circadian desynchronisation. It modulates suprachiasmatic nucleus receptors to realign the body's internal clock with external light–dark cues, which is disrupted by rotating shift work. The research dosing is 20mg intranasal nightly for 14 days to establish realignment, then as-needed dosing during schedule transitions. Pinealon does not induce drowsiness. It restores the timing signal that coordinates when sleep-permissive brain states occur, so it must be paired with appropriate light exposure (bright light during desired wake periods, darkness during desired sleep periods) to be effective.

Modify training load to stay below the pain threshold but maintain movement. Complete rest often worsens tendinopathy by reducing mechanical stimulus required for proper collagen alignment. Research on tendon healing shows that controlled eccentric loading (slow, lengthening contractions) promotes collagen fiber organization along lines of stress. Use BPC-157 (500mcg daily) to accelerate vascular response and reduce recovery time between training sessions. Monitor pain levels closely. If pain increases during or after activity despite peptide use, training intensity exceeds tissue capacity and must be reduced.

Alternate between Dihexa (5mg oral daily for 30 days) and P21 (1mg subcutaneous every 48 hours for 30 days) in 60-day cycles. Dihexa creates new synaptic pathways; P21 strengthens consolidation of learned material. Continuous use of either compound leads to receptor desensitization. Cycling maintains responsiveness while targeting complementary memory stages.

Administer it subcutaneously near the injury site instead. Oral routes have unproven bioavailability. Gastric acid breaks peptide bonds, and the molecule likely degrades before reaching systemic circulation. No peer-reviewed human trials confirm that oral BPC-157 achieves therapeutic plasma concentrations. Subcutaneous injection bypasses first-pass metabolism and delivers the compound directly to target tissues.

This combination is effective but requires a 4–6 week observation window to detect meaningful changes. Cerebrolysin's anti-inflammatory effects accumulate slowly, and immediate sleep improvements are unlikely. Administer Cerebrolysin 3x weekly (Monday, Wednesday, Friday) and DSIP nightly. The dual approach addresses both the inflammatory upstream cause and the acute sleep architecture disruption. Monitor cortisol and IL-6 levels at baseline and week 4 to confirm pathway engagement before extending the protocol.

Use Dihexa if the endpoint is acquisition or consolidation of new spatial or declarative memories. Its HGF/c-Met mechanism directly increases dendritic spine density in the hippocampus, which is the structural substrate of memory encoding. Use Cerebrolysin if the study involves neuroprotection after injury or hypoxia. Its neurotrophic factor cocktail reduces excitotoxic damage and supports neuronal survival, but it does not show the same synaptic plasticity effects as Dihexa in healthy neurons.

Most research-grade peptides are shipped as lyophilized (freeze-dried) powder stable at −20°C. Once reconstituted with bacteriostatic water, they must be refrigerated at 2–8°C. A single temperature excursion above 8°C. Even for 30 minutes. Can denature protein structure irreversibly. Unlike medication that changes color or develops particles when degraded, denatured peptides often look identical to stable solutions. There's no at-home test for potency loss. If reconstituted peptides are left unrefrigerated, discard them.

Apply GHK-Cu or Matrixyl-3000 topically twice daily for 12–16 weeks minimum. Mature scars (older than one year) require longer treatment timelines because collagen turnover in dormant scar tissue is slower than in active wounds. The peptide must reach fibroblasts that have downregulated activity. This takes sustained signaling. Clinical studies showing 30–40% improvement in mature scars used treatment durations of 16–24 weeks, not 4–6 weeks. BPC-157 offers minimal benefit for scars older than eight weeks because it targets the proliferative phase, which has already ended.

DSIP is the only peptide ranked here with same-night efficacy. Intranasal administration 30 minutes before sleep extends Stage 3 duration within one sleep cycle. The compound has a 15-minute plasma half-life but remains active in CNS tissue for 4–6 hours due to receptor binding kinetics, which is why a single pre-sleep dose affects the entire night without causing next-day sedation. Research protocols use 1mg intranasal DSIP reconstituted in bacteriostatic water. Doses above 2mg do not produce additional deep sleep extension and may cause morning grogginess.